disease
4-hydroxyandrostenedione (4-OHA), the       first selective aromatase inhibitor, has been shown to reduce serum estrogen       concentrations and cause complete and partial responses in approximately 25% of       patients with hormone responsive disease who have relapsed from previous       endocrine treatment.
4-hydroxyandrostenedione (4-OHA), the       first selective aromatase inhibitor, has been shown to reduce serum estrogen       concentrations and cause complete and partial responses in approximately 25% of        @OBJECT$   @PREDICAT$  hormone responsive  @SUBJECT$  who have relapsed from previous       endocrine treatment.